Appendix 1. Patients' demographics and characteristics*

	Baseline (n=117)	12 months (n=117)	24 months (n=105)
Age (years) Mean±SD (min-max)	11.4±4.9 (0.1-18.0)		
Gender n			
Female/Male	37/80	37/80	32/73
BMI Mean±SD (min-max)	18.9±4.5 (12.3-34.2)	19.6±4.5 (12.0-34.2)	19.8±4.9 (10.9-38.3)
Hypertension			
Yes/No	35/82	46/71	43/62
CKD stage n (%)			
Stage 2	17 (14.5)	18 (15.4)	12 (11.4)
Stage 3a	35 (29.9)	18 (15.4)	18 (17.1)
Stage 3b	33 (28.2)	35 (29.9)	24 (22.9)
Stage 4	27 (23.1)	35 (29.9)	38 (36.2)
Stage 5	5 (4.3)	11 (9.4)	13 (12.4)
CKD etiology n (%)			
CAKUT	64 (54.7)	-	-
Inborn error of metabolism	13 (11.1)	-	-
Neurogenic bladder	12 (10.3)	-	-
Cystic kidney disease	12 (10.3)	-	-
Glomerular disease	4 (3.4)	-	-
Others	12 (10.3)	-	-
eGFR (mL/min/1.73m^2) Mean±SD (min-max)	42±18 (10-86)	37±17 (10-79)	35±19 (9-89)
Hemoglobin (g/dL) Mean±SD (min-max)	11.9±1.8 (7.2-16.5)	11.8±1.8 (7.5-17.0)	12.0±1.9 (7.4-17.7)
Ferritin (ng/mL) Mean±SD (min-max)	108±115 (5-581)	128±153 (4-866)	130±164 (4-759)
Serum calcium (mg/dL) Mean±SD (min-max)	9.6±0.6 (8.3-11.8)	9.6±0.6 (7.9-11.3)	9.6±0.7 (7.2-11.5)
Serum phosphorus (mg/dL) Mean±SD (min-max)	4.5±1.0 (2.4-9.1)	4.5±0.9 (2.1-7.7)	4.5±0.9 (2.4-7.6)
Serum alkaline phosphatase (U/L) Mean±SD (min-max)	247±228 (26-2010)	207±102 (65-472)	224±111 (56-549)
Parathyroid hormone (pg/mL) Mean±SD (min-max)	149±158 (18-949)	199±300 (17-1872)	218±324 (10-2073)
Urinary protein/creatinine (mg/mg) Mean±SD (min-max)	1.69±2.11 (0.07-12.14)	1.61±2.44 (0.08-15.82)	1.87±3.57 (0.09-31.55)
Medication*			
Antihypertensive drugs			
1 drug n (%)	23 (19.7%)	29 (24.8%)	22 (21.0%)
2 drugs n (%)	8 (6.8%)	15 (12.8%)	16 (15.2%)
3 drugs n (%)	4 (3.4%)	2 (1.7%)	5 (4.8%)
Sodium bicarbonate n (%)	43 (36.8%)	67 (57.3%)	64 (61.0%)
Calcium carbonate n (%)	29 (24.8%)	39 (33.3%)	41 (39.1%)
Sevelamer n (%)	0 (%0)	1 (0.9%)	2 (1.9%)
Calcitriol n (%)	26 (22.2%)	42 (35.9%)	59 (56.2%)
Vitamin D n (%)	33 (28.2%)	44 (37.6%)	44 (41.9%)
ESAs n (%)	9 (7.7%)	10 (8.6%)	18 (17.1%)
Oral iron n (%)	44 (37.6%)	60 (51.3%)	61 (58.1%)
Antiepileptic drugs n (%)	5 (4.3%)	5 (4.3%)	5 (4.8%)
Oxybutynin n (%)	19 (16.2%)	21 (18.0%)	17 (16.2%)
Immunosupressive drugs n (%)	5 (4.3%)	5 (4.3%)	5 (4.8%)
Tiopronin n (%)	1 (0.9%)	1 (0.9%)	1 (1.0%)
Cysteamine n (%)	3 (2.6%)	3 (2.6%)	3 (2.9%)
Pyridoxine n (%)	3 (2.6%)	3 (2.6%)	3 (2.9%)

BMI: Body mass index CAKUT: Congenital anomalies of the kidney and the urinary tract, CKD: Chronic kidney disease, eGFR: estimated glomerular filtration rate, ESAs: Erythropoiesis-stimulating agents,* Medication data were recorded at the time of sampling

Appendix 2. Correlations between baseline levels of sFas, sFasL, and sE-selectin and simultaneously biochemical parameters

		Serum sFas	Serum sFasL	Serum sE-selectin	Urinary sFas/Cr	Urinary sFasL/Cr	Urinary sE-selectin/Cr
Hemoglobin (g/dL)	r	0.098	-0.152	0.145	-0.238	-0.245	-0.199
	p	0.296	0.103	0.121	**0.010**	**0.008**	**0.033**
Serum Ferritin (ng/mL)	r	0.169	0.007	0.075	-0.105	-0.206	-0.200
	p	0.102	0.943	0.473	0.317	**0.047**	0.055
Serum calcium (mg/dL)	r	-0.085	0.078	0.161	-0.182	-0.171	-0.155
	p	0.366	0.404	0.085	0.051	0.067	0.098
Serum phosphorus (mg/dL)	r	-0.109	0.138	0.026	0.015	0.112	0.125
	p	0.250	0.142	0.781	0.874	0.236	0.188
Parathyroid hormone (pg/mL)	r	0.218	-0.037	0.131	0.156	0.100	0.029
	p	**0.027**	0.713	0.187	0.117	0.315	0.776
Urinary protein/creatinine (mg/mg)	r	0.071	0.017	0.142	0.703	0.663	0.716
	p	0.452	0.856	0.133	**<0.0001**	**<0.0001**	**<0.0001**

Cr: creatinine, eGFR: estimated glomerular filtration rate, sFas: soluble Fas, sFasL: soluble Fas Ligand, sE-selectin: soluble E-selectin; r-Spearman's correlation coefficient.

Appendix 3. Correlations among baseline levels of sFas, sFasL, and sE-selectin

		Serum sFas	Serum sFasL	Serum sE-selectin	Urinary sFas/Cr	Urinary sFasL/Cr	Urinary sE-selectin/Cr
Serum sFas	r	-	-0.239	0.443	0.046	-0.038	-0.032
	p	-	**0.009**	**<0.0001**	0.623	0.683	0.730
Serum sFasL	r	-0.239	-	-0.056	0.158	0.250	0.173
	p	**0.009**	-	0.550	0.091	**0.007**	0.064
Serum sE-selectin	r	0.443	-0.056	-	0.163	0.216	0.319
	p	**<0.0001**	0.550	-	0.081	**0.020**	**<0.0001**
Urinary sFas/Cr	r	0.046	0.158	0.163	-	0.805	0.726
	p	0.623	0.091	0.081	-	**<0.0001**	**<0.0001**
Urinary sFasL/Cr	r	-0.038	0.250	0.216	0.805	-	0.845
	p	0.683	**0.007**	**0.020**	**<0.0001**	-	**<0.0001**
Urinary sE-selectin/Cr	r	-0.032	0.173	0.319	0.726	0.845	-
	p	0.730	0.064	**<0.0001**	**<0.0001**	**<0.0001**	-

Cr: creatinine, sFas: soluble Fas, sFasL: soluble Fas Ligand, sE-selectin: soluble E-selectin
r-Spearman's correlation coefficient.

Appendix 4. Correlations between baseline serum levels of sFas, sFasL, and sE-selectin and serum levels of HSPs

		Serum sFas	Serum sFasL	Serum sE-selectin
Serum HSP27	r	0.011	-0.108	-0.142
	p	0.909	0.245	0.127
Serum HSP40	r	0.102	0.050	-0.092
	p	0.272	0.595	0.324
Serum HSP47	r	0.019	0.068	-0.048
	p	0.840	0.463	0.605
Serum HSP60	r	0.057	-0.086	-0.023
	p	0.539	0.356	0.804
Serum HSP70	r	0.037	0.029	-0.058
	p	0.689	0.756	0.535
Serum HSP72	r	0.154	-0.173	0.077
	p	0.096	0.063	0.410
Serum HSP90	r	-0.110	0.004	-0.097
	p	0.237	0.965	0.297
Serum anti-HSP60	r	-0.032	-0.217	-0.151
	p	0.729	**0.019**	0.103
Serum anti-HSP70	r	-0.128	0.247	-0.045
	p	0.168	**0.007**	0.629

HSP: heat shock protein, sFas: soluble Fas, sFasL: soluble Fas Ligand, sE-selectin: soluble E-selectin; r-Spearman's correlation coefficient